"O Hospital Mãe de Deus atua, desde 1979, oferecendo soluções completas em saúde, diagnóstico e tratamento, com foco em atendimento humanizado, seguro e centralizado na resolução de cada caso. Para melhor atender aos pacientes, conta com uma estrutura de 327 leitos ativos, área construída de aproximadamente 55 mil m², onde concentra 2.000 equipamentos de tecnologia avançada, uma equipe de profissionais altamente qualificados e com experiência clínica, treinados por mais de 2.300 médicos credenciados. É mantido pela instituição filantrópica AESC - Associação Educadora São Carlos, da Congregação das Irmãs Missionárias de São Carlos Borromeo Scalabrinianas."

During the past decade, Hospital Mãe de Deus conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 13 clinical trials were completed, i.e. on average, 68.4% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 6 clinical trials were completed. i.e. 54.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Mãe de Deus" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Pfizer" with 3 trials sponsored, "Agenus Inc." with 2 trials sponsored, "Bayer" with 2 trials sponsored and "Boehringer Ingelheim" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Mãe de Deus" #1 collaborator was "CytoDyn, Inc." with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Mãe de Deus" are "Cervical Cancer" (3 trials), "COVID-19 Pneumonia" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Coronary Artery Disease" (2 trials) and "Acute Ischemic Stroke" (1 trials). Many other conditions were trialed in "Hospital Mãe de Deus" in a lesser frequency.

Most popular intervention types in "Hospital Mãe de Deus" are "Drug" (32 trials), "Other" (4 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Cyclophosphamide" (3 trials), "Paclitaxel" (3 trials), "AGEN2034" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Mãe de Deus" are 33 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Mãe de Deus". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Hospital Mãe de Deus, 2 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Mãe de Deus, 3 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".

Hospital Mãe de Deus has several departments that took part in Clinical trials: "Centro de Oncologia e Radioterapia (COR) Mae de Deus" - 2 trials